Efficiency of “Noliprel A Bi-forte”
in male elderly population with chronic obstructive pulmonary disease
and concomitant hypertension

Background. Chronic obstructive pulmonary disease (COPD) and hypertension (HTN) are linked to each other by different associated factors which are playing an important role in their clinical course and progression. “Pulmonigenic” mechanisms of HTN in COPD are discussed due to the frequent onset of HTN few years after the first clinical presentations of COPD and due to the association between blood pressure (BP) elevation and exacerbation of pulmonary disease with progression of bronchial obstruction and hypoxemia worsening. Design and methods. Our study group consisted of 30 male patients (mean age 62,4 ± 4,2 years) with COPD and concomitant HTN. The control group was formed by 30 male hypertensive patients (mean age 63,7 ± 3,9 years). The higher rate of patients with concomitant COPD and HTN demonstrated adverse BP daily profile «nightpeakers» than in control group. This might be an additional risk factor for cardiovascular complications such as a myocardial infarction and a brain stroke. The search for combinations of antihypertensive drugs not influencing the bronchial patency and having longer antihypertensive effect duration is ongoing in order to reduce the risk of complications. In our study “Noliprel A Bi-Forte” was an investigational drug (Perindopril Arginine 10 mg and Indapamide 2,5 mg). Administration of a single dose “Noliprel A Bi-Forte” led to a reliable BP decrease and stabilization according to the results of daily BP monitoring. Serious adverse effects were not registered during the study. 

1. Поликарпов Л. С., Хамнагадаев И. И., Манчук В. Т., Деревянных Е. В., Москвитина В. В., Яскевич Р. А. Социально-эпидемиологическая характеристика артериальной гипертонии в условиях Севера и Сибири. Сибирское медицинское обозрение. 2008;52(4):92– 95. [Polikarpov LS, Hamnagadayev II, Manchuk VT, Derevyannykh EV, Moskvitin VV, Yaskevich RA. Social and epidemiological characteristic of arterial hypertension in conditions of the North and Siberia. Sibirskoye Meditsinskoye Obozreniye = Siberian medical review. 2008;52(4):92–95. In Russian].

2. Поликарпов Л. С., Хамнагадаев И. И., Яскевич Р. А., Деревянных Е. В. Артериальная гипертония (распространенность, профилактика, адаптация и реадаптация к различным экологическим условиям). Красноярск; 2010. 289 c. [Polikarpov LS, Khamnagadayev II, Yaskevich RA, Derevyannykh EV. Arterial hypertension (prevalence, prevention, adaptation and readaptation to various ecological conditions). Krasnoyarsk; 2010. 289 p. In Russian].

3. Perera PN, Armstrong EP, Sherrill DL, Skrepnek GH. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD. 2012;9(2):131–141.

4. Кароли Н. А., Ребров А. П. Современные подходы к лечению хронической сердечной недостаточности у больных хронической обструктивной болезнью легких. Consilium Medicum. 2014;16(3):13–22. [Karoli NA, Rebrov AP. Modern approaches to treatment of chronic heart failure in patients with chronic obstructive pulmonary disease. Consilium Medicum. 2014;16(3):13–22. In Russian].

5. Козлов Е. В., Поликарпов Л. С., Петрова М.М. Деревянных Е. В. Системное артериальное давление в легочном стволе и вариабельность суточного мониторинга артериального давления у лиц мужского пола при коморбидности хронической обструктивной болезни легких и артериальной гипертонии. Сибирское медицинское обозрение. 2013;83(5):64–69. [Kozlov EV, Polikarpov LS, Petrova MM, Derevyannykh EV. System arterial pressure in pulmonary trunk and variability of arterial pressure daily monitoring in males with comorbidity of chronic obstructive pulmonary disease and arterial hypertension. Sibirskoye Meditsinskoye Obozreniye = Siberian Medical Review. 2013;83(5):64–69. In Russian].

6. Кобалава Ж. Д., Котовская Ю. В. Мониторирование артериального давления: методические аспекты и клиническое значение. М.: Медицинская книга; 1999. 234 c. [Kobalava ZhD, Kotovskaya YuV. Monitoring of arterial pressure: methodical aspects and clinical value. Moscow: Medical book; 1999. 234 p. In Russian].

7. Цибульская Н. Ю., Поликарпов Л. С., Петрова М. М. Клинико-функциональные особенности больных артериальной гипертонией в зависимости от суточных биоритмов. Сибирское медицинское обозрение. 2012;78(6):24–28. [Tsibulskaya NYu, Polikarpov LS, Petrova MM. Clinical and functional features of patients with arterial hypertension depending on daily biorhythms. Sibirskoye Meditsinskoye Obozreniye = Siberian Medical Review. 2012;78(6):24–28. In Russian].

8. Rothwell P, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375(9718):895–905.

9. Ли В. В., Задионченко В. С., Адашева Т. В., Павлов С. В., Малиничева Ю. В., Саморукова Е. И. и др. Артериальная гипертония у больных хронической обструктивной болезнью легких — в поисках фенотипов. Часть I. Архив внутренней медицины. 2013;1(9):19–24. [Li VV, Zadionchenko VS, Adashev TV, Pavlov SV, Malinicheva YuV, Samorukova EI et al. Arterial hypertension in patients with chronic obstructive pulmonary disease — in search of phenotypes. Part I. Archive of Internal Medicine. 2013;1(9):19–24. In Russian].

10. Cupte S, Wolin M. Relationships between vascular oxygen sensing mechanisms and hypertensive disease processes. Hypertension. 2012;60(2):269–275.